| (Values in U.S. Thousands) | Nov, 2022 | Aug, 2022 | May, 2022 | Feb, 2022 | Nov, 2021 |
| Sales | 110 | 90 | 0 | 0 | 30 |
| Sales Growth | +22.22% | unch | unch | -100.00% | unch |
| Net Income | -730 | -850 | -180 | -450 | -1,010 |
| Net Income Growth | +14.12% | -372.22% | +60.00% | +55.45% | -114.89% |
Bioasis Technologies Inc (BIOAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
biOasis Technologies Inc. is a biopharmaceutical company. It is focused on developing and commercializing proprietary pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The Company is engaged in the development of a vector (Transcend) for the transport of therapeutic agents across the blood brain barrier and the development of an in vitro diagnostic assay to assist physicians in diagnosis of Alzheimer's disease (Cognitest). biOasis Technologies Inc. is headquartered in Vancouver, Canada.
Fiscal Year End Date: 02/28